← All trials
NCT07253584
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2023
- Primary completion
- Jun 23, 2025
- Completion date
- Jun 30, 2025
- First posted
- Nov 28, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 720
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Lead sponsor
- Jiao Tong UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.